Neothetics to Release Second Quarter 2015 Financial Results

SAN DIEGO, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ: NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that it will release its second quarter 2015 financial results before the market opens on Thursday, August 13, 2015.

To receive Neothetics' press releases and other investor information, please go to the Investor Relations page of the company's website at investors.neothetics.com and register for email alerts.

About Neothetics, Inc.

Neothetics is a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market. The lead product candidate, LIPO-202, is for central abdominal bulging due to subcutaneous fat in non-obese subjects, an indication for which there is no FDA-approved drug. If approved, LIPO-202 may be a best-in-class non-surgical, non-ablative procedure and first-in-class injectable formulation for localized fat reduction and body contouring. For more information on Neothetics, please visit www.neothetics.com.

Neothetics, LIPO-202, LIPO-102 and the Neothetics logo are trademarks or registered trademarks of Neothetics, Inc. Other names and brands may be claimed as the property of others.

CONTACT: COMPANY CONTACT:
         Susan A. Knudson
         Chief Financial Officer
         858-750-1008
         [email protected]

         INVESTOR CONTACT:
         Fara Berkowitz, PharmD
         Investor Relations and Corporate Strategy
         [email protected]

         MEDIA CONTACT:
         Margaux Stack-Babich
         Canale Communications
         619-849-5385
         [email protected]

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
• RenovoRx regains Nasdaq minimum bid price compliance